Companies/Sirona Biochem Corp.

Company profile

Sirona Biochem Corp.

OTC: SRBCF · Healthcare · Biotechnology

Canadian filerHQ Vancouver, BCReports USD

#1092 of 1,394 Healthcare companies by revenuebottom-decile growth

EA Score

——

FH —DQ —GM —SS 41

v0.1 · 5/100 weight · pillars only

↑ listing tenure, disclosure history · ↓ revenue growth (YoY), operating margin

Methodology →

Revenue TTM

-$12.1k

Rev growth YoY (TTM)

-119.3%

Net income (FY)

-$1.9M

Employees

Market cap

$1.6M

Financials — latest annual

SEC EDGAR · USD-normalized

ConceptUSDNativeFY

Revenue$25.8k34.8k CAD2023

Net income-$1.9M-2.5M CAD2023

Operating income-$1.8M-2.4M CAD2023

Total assets$744.1k1.0M CAD2023

Liabilities$2.6M3.5M CAD2023

Equity-$1.8M-2.5M CAD2023

Revenue trend

FY2017 – FY2023 · USD

$4.2k

FY17

$993.5k

FY18

$102.2k

FY19

$78.5k

FY20

$213.1k

FY21

$521.9k

FY22

$25.8k

FY23

Revenue by segment

No segmentation disclosed for this filer. n/a

The read

Sirona Biochem Corp. booked $25.8k in FY2023 revenue, contracting 95% year over year — among the slowest-growing Healthcare companies we track, at a -7312.4% net margin.

Peers · Healthcare

Procyon Corporation——Kelyniam Global, Inc.——Azitra, Inc.29D Aclarion, Inc.36D

Key facts

CEOHoward J. Verrico

SectorHealthcare

IndustryBiotechnology

HeadquartersVancouver, BC

ExchangeOTC: SRBCF

Employees10

IPO date2013-02-12

Latest filings

No filings loaded — no CIK (non-SEC filer).

Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.